-
Product Insights
NewNet Present Value Model: Innovent Biologics Inc’s Mazdutide
Empower your strategies with our Net Present Value Model: Innovent Biologics Inc's Mazdutide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Turnstone Biologics Corp’s TIDAL-01
Empower your strategies with our Net Present Value Model: Turnstone Biologics Corp's TIDAL-01 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: CanSino Biologics Inc’s Pneumococcal Vaccine
Empower your strategies with our Net Present Value Model: CanSino Biologics Inc's Pneumococcal Vaccine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Biologic For Crohn’s Disease in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Biologic For Crohn's Disease in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Biologic For Crohn's Disease in Crohn's Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Biological-162 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Biological-162 in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Biological-162 in Hepatitis B Drug Details: Antibody (162) is under development for...
-
Sector Analysis
Soft Tissue Biologics Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Soft Tissue Biologics Market Report Overview The Soft Tissue Biologics market size was $361.1 Million in 2023. The market is expected to grow at a CAGR of more than 2% during 2023-2033. Soft Tissue Biologics are used in surgical procedures to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. The market focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles tendon. Soft...
-
Sector Analysis
NewPeripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Peripheral Artery Disease Marketed and Pipeline Drugs Report Overview PAD is an atherosclerotic disease in which the formation of atherosclerotic plaque causes narrowing of the arteries and poor perfusion to the limbs. This can progress to arterial occlusion and chronic limb-threatening ischemia (CLTI). PAD can happen in any blood vessel, but it is more common in the legs than the arms. Key Mechanisms of Action (Marketed) ·      Receptor Agonist ·      Enzyme Inhibitor ·      Biological Factor Activator ·      Ligand Inhibitor ·      ...
-
Sector Analysis
NewReconstruction Meshes Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Reconstruction Meshes Market Report Overview The Reconstruction Meshes market size was $2.38 billion in 2023. Factors such as the rising number of breast reconstruction procedures and the growing prevalence of Pelvic Organ Prolapse (POP) will drive the market growth at a CAGR of more than 1% from 2023 to 2033. Reconstruction Meshes Market Outlook 2023-2033 ($ Billion) Buy the Full Report for More Insights on the Reconstruction Meshes Market Forecast, Download a Free Sample Report The Reconstruction Meshes market research...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.